Lupin has launched Olmesartan Medoxomil tablets 5 mg, 20 mg and 40 mg in the US markets having received an approval from the United States Food and Drug Administration (USFDA) earlier.
The company’s Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Benicar tablets. It is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, to lower blood pressure. Benicar tablets had US sales of $681 million as per IMS MAT July 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
